Arylamine N-acetyltransferase 1 (NAT1) expression is reported to affect proliferation, invasiveness, and growth of cancer cells. MDA-MB-231 breast cancer cells were engineered such that NAT1 expression was elevated or suppressed, or treated with a small molecule inhibitor of NAT1. The MDA-MB-231 human breast cancer cell lines were engineered with a scrambled shRNA, a NAT1 specific shRNA or a NAT1 overexpression cassette stably integrated into a single flippase recognition target (FRT) site facilitating incorporation of these different genetic elements into the same genomic location. NAT1-specific shRNA reduced NAT1 activity in vitro by 39%, increased endogenous acetyl coenzyme A levels by 35%, and reduced anchorage-independent growth (sevenfold) without significant effects on cell morphology, growth rates, anchorage-dependent colony formation, or invasiveness compared to the scrambled shRNA cell line. Despite 12-fold overexpression of NAT1 activity in the NAT1 overexpression cassette transfected MDA-MB-231 cell line, doubling time, anchoragedependent cell growth, anchorage-independent cell growth, and relative invasiveness were not changed significantly when compared to the scrambled shRNA cell line. A small molecule (5E)-[5-(4-hydroxy-3,5-diiodobenzylidene)-2-thioxo-1,3-thiazolidin-4-one (5-HDST) was 25-fold more selective towards the inhibition of recombinant human NAT1 than N-acetyltransferase 2. Incubation of MDA-MB-231 cell line with 5-HDST resulted in 60% reduction in NAT1 activity and significant decreases in cell growth, anchorage-dependent growth, and anchorage-independent growth. In summary, inhibition of NAT1 activity by either shRNA or 5-HDST reduced anchorageindependent growth in the MDA-MB-231 human breast cancer cell line. These findings suggest that human NAT1 could serve as a target for the prevention and/or treatment of breast cancer.
| INTRODUCTION
Arylamine N-acetyltransferase 1 (NAT1) historically is identified as a phase II drug and carcinogen metabolizing enzyme that catalyzes the transfer of an acetyl group from acetyl-coenzyme A (AcCoA) to the amine nitrogen of arylamine and hydrazine compounds. Recently human NAT1 was shown to catalyze hydrolysis of AcCoA in the presence of folate. 1, 2 NAT1 expression is elevated in invasive and lobular breast carcinomas when compared to normal breast tissue. 3 This overexpression of NAT1 was confirmed at the mRNA level and by immunohistological analysis in 108 breast cancer samples that demonstrated a strong association of NAT1 staining and estrogen receptor-positive tumors. 3 Elevated NAT1 expression in estrogen receptor-positive tumors has been observed in multiple studies. 4, 5 Also, elevated NAT1 expression is associated with breast cancer bone metastasis. 6, 7 Overexpression of NAT1 in a normal luminal epithelialderived cell line conferred enhanced growth properties and etoposide resistance compared to control cells that had been transfected with an empty vector. 3 Subsequent studies demonstrated that a small molecule inhibitor of NAT1 activity caused decreased cell growth and reduced ability of MDA-MB-231 human breast cancer cells to grow in soft agar. 8 A lentiviral-based NAT1 shRNA, which reduced NAT1 activity by 74%, reduced cell invasion by 50% in MDA-MB-231
human breast cancer cells. 8 NAT1 activity is cell-cycle phasedependent showing an association between high NAT1 activity and accelerated progression through the cell cycle in HaCaT keratinocytes. 9 RNAi-mediated knockdown of NAT1 by approximately 85% in the colon cancer cell line HT-29 is associated with increased cell-cell contact inhibition, loss of cell viability at confluence, and attenuation of anchorage-independent cell growth. 10 Human NAT1 activity is modified by polymorphism, but can also be regulated by microRNA, epigenetic, and/or translational and posttranslational control. 5, [11] [12] [13] NAT1 transcript levels can be regulated by extracellular stimuli acting on glucocorticoid or androgen receptors. 14, 15 Exposure to NAT1 substrates can increase NAT1 degradation, which results in decreased NAT1 activity. 12, 13 Oxidative stress can reversibly or irreversibly inactivate NAT1. 16, 17 NAT1 inhibitors have been reported including cisplatin, 18 curcumin, 19, 20 disulfiram, 21 and rhodanine derivatives. 8, 22 The ability to control the level of NAT1 activity and expression by various means may reduce cancer growth or metastasis.
To investigate further whether modulation of NAT1 activity can affect cancer cell growth and invasion properties, MDA-MB-231
human breast cancer cells were engineered with either a scrambled shRNA, a NAT1 specific shRNA or a NAT1 overexpression cassette.
These modifications were stably integrated into a single flippase recognition target (FRT) site facilitating incorporation of these different genetic elements into the same genomic location. We also investigated the effects of an NAT1 small molecule inhibitor. We used the Sure Silencing™ shRNA plasmid described previously, 10 
| Cell line generation and culturing conditions
The breast adenocarcinoma cell line, MDA-MB-231, was purchased from ATCC (Manassas, Virginia). Cells were cultured in Dulbecco's Modified Eagles Medium (DMEM) media, high glucose with the addition of fetal bovine serum to 10% and glutamine to 2 mM. SureSilencing™
Predesigned shRNA and NAT1 knockdown shRNA plasmids were purchased from SA Biosciences (Frederick, MD). Initial screening found that the NAT1 shRNA Clone 1 reduced NAT1 activity by 29% while NAT1 shRNA Clone 3 reduced NAT1 activity by 50%. Further studies were conducted with NAT1 shRNA Clone 3 because it was used in previous experiments 10 and resulted in the greatest reduction in NAT1 expression. The shRNA sequence for the scrambled shRNA and NAT1
shRNA clone 3 were transferred from the pGeneclip™ vector to the pcDNA5/FRT vector. The NAT1 overexpression plasmid NATb/ NAT1*4 in pcDNA5/FRT was described previously.
23
A MDA-MB-231 breast cancer cell line with a single FRT site was constructed using the Flp-In System (Life Technologies, Grand Island, NY) as described previously. 24 Once an MDA-MB-231 cell line was constructed with a single FRT site in a transcriptionally active region, we transfected the shRNA plasmids, and the NAT1 overexpression plasmid to deliver the cassettes to the same genetic location. The pcDNA5/FRT plasmids containing the scrambled shRNA, NAT1 specific shRNA plasmid or the NAT1 overexpression plasmid NATb/NAT1*4 23 were co-transfected with pOG44, a Flp recombinase expression plasmid, using Amaxa Cell Line Nucleofector Kit V (Lonza, Basel, Switzerland)
following the manufacturer's recommendations. Since the pcDNA5/FRT vector contains a hygromycin resistance cassette, cells were passaged in complete DMEM containing 500 μg/mL hygromycin to select for cells with the pcDNA5/FRT plasmid stably integrated into their genomic DNA. Hygromycin-resistant colonies were selected approximately 2 weeks after transfection and isolated using cloning cylinders. Unless otherwise stated, experiments using cell lines were performed with cells in log phase of growth.
In summary, the following MDA-MB-231 cell lines were constructed:
1. Scrambled shRNA cell line stably transfected with scrambled shRNA as a control cell line to which other cell lines are compared.
2. NAT1 knockdown cell line stably transfected with NAT1 specific shRNA.
3. NAT1 overexpression cell line stably transfected with the NATb/ NAT1*4 cassette.
The constructed MDA-MB-231 cell lines were authenticated by the ATCC Short Tandem Repeat (STR) profiling cell authentication service.
| Measurement of N-acetylation in vitro
In vitro assays using the NAT1 selective substrate para-aminobenzoic acid (PABA) were conducted and the N-acetyl-PABA product was separated and quantitated as described. 25 Briefly, cells were scraped from the plate, washed in 1× phosphate-buffered saline (PBS), and reactions. N-acetyl-PABA product was separated and quantitated as described above. Lineweaver-Burke inhibition plots were generated and analyzed using GraphPad Software.
| Measurement of N-acetylation in situ
Measurement of N-acetylation in situ was determined by spiking media with a known concentration of PABA as described. 29 The cells were incubated at 37°C for 48 h with media containing 500 μM PABA.
Media were collected and 1/10 total collected media volume of 1 M acetic acid was added. Acidified media were centrifuged at 15 000g for 10 min. There were four independent measurements (N = 4) performed in triplicate for each cell line.
Resulting supernatants from in vitro and in situ NAT1 activity assays were injected into a reverse phase C18 column (125 mm × 4 mm; 5 µM pore size). Reactants and products were eluted using a Beckman System Gold high performance liquid chromatography (HPLC) system. HPLC separation of N-acetyl-PABA was achieved using a gradient of 96:4 sodium perchlorate pH 2.5:
acetonitrile at 280 nm. The data for scrambled shRNA, knockdown and overexpression cell lines are represented as mean ± SEM and analyzed statistically by a one-way ANOVA and Bonferroni post test.
| Measurement of endogenous AcCoA levels
Endogenous 
| Quantitation of NAT1 mRNA levels
NAT1 mRNA levels were measured as described previously. 29 
| Determination of doubling time of cell lines
Twenty-five thousand cells were plated in triplicate in six-well plates and allowed to grow for 5 consecutive days. Cells were plated on day 1 and allowed to equilibrate for 24 h before making the first count on day 2 followed by counts on days 3, 4, 5, and 6 using a cell counter. A cell doubling rate was calculated for each day using Equation 1 (shown below) and then rates were averaged over the 5 day time period to get a final cell doubling rate.
In the equation, b = cell number on day n, a = cell number on day n-1, t b = hours passed since plating when cells were counted on day n, and 
| Transwell assays to assess relative invasive ability
Transwell assays were performed by depositing 1 × 10 5 cells in 100 μL of DMEM containing 0.2% FBS in the top chamber of the transwell and 600 μL of complete media in the bottom chamber. 5-HDST (ranging from 0 to 100 μM) was added to media on both sides of the membrane.
Cells were allowed to invade across a membrane of Matrigel (Life Technologies). After 24 h, cells on the top side of the membrane were removed with a sterile cotton swab. Cells that invaded across the membrane were quantified using the Alamar Blue cell quantitation assay. Three separate determinations performed in triplicate were made (N = 3). The data are represented as means ± SEM, and were analyzed statistically by one-way ANOVA and Bonferroni post hoc test.
| RESULTS

| Effects of reduced and elevated NAT1 activity on MDA-MB-231 breast cancer cells
The stable partial knockdown of NAT1 reduced in vitro PABA NAT1 activity to 61% of the scrambled shRNA cell line ( Figure 1A ) and in situ PABA NAT1 acetylation to 62% of the scrambled shRNA cell line Figure 3B) . However, the knockdown of NAT1 caused a significant ∼85% decrease (P < 0.0001) in anchorage-independent growth, whereas the overexpression of NAT1 had no significant effect ( Figure 3C ). Neither knockdown of NAT1 with shRNA nor overexpression of NAT1 had a significant effect on relative invasive ability ( Figure 3D ).
| Effects of small molecule NAT1 inhibitor on MDA-MB-231 breast cancer cells
To investigate further whether the effects of NAT1 knockdown on cell growth and invasion ability were due to reduced NAT1 activity, we tested the effects of a small molecule inhibitor of NAT1. Figure 4A ) significantly (P < 0.0001) reduced PABA N-acetylation in situ in a concentration-dependent manner ( Figure 4B ).
5-HDST (
A single dose of 5-HDST reduced PABA N-acetylation in situ for at least 6-days ( Figure 4B ). The IC 50 for 5-HDST inhibition of PABA N-acetylation in situ was similar on day 1 (67.1 μM) and day 6 (47.6 ± 1.1 μM; Figure 4C ).
Cells treated with 5-HDST ranging from 0 to 50 μM over a period of up to 6 days produced no significant effects on cell growth Figure 5C ). Incubation with 5-HDST had no effect on relative invasion ability until concentrations of 5-HDST exceeded 75 μM (P < 0.05) ( Figure 5D ).
| Characterization of recombinant human NAT1 and NAT2 inhibition by 5-HDST
5-HDST exhibited 25-fold higher selectivity towards inhibition of recombinant human NAT1 (IC 50 = 0.732 ± 0.012 µM; Figure 6A ) than human NAT2 (IC 50 = 18.7 ± 0. 2 µM; Figure 6B ). 5-HDST inhibition of recombinant human NAT1 was uncompetitive ( Figure 6C ).
| DISCUSSION
We investigated whether differences in human NAT1 expression affect breast cancer cell growth and metastatic properties. The novelty of our approach included NAT1 knockdown and overexpression with a FRT system, which facilitates investigations of decreased or increased NAT1 expression independent of off-target effects because all the expression cassettes were inserted into the same genomic location.
NAT1 knockdown using shRNA resulted in approximately 39%
reduction in NAT1 in vitro activity, a comparable 35% increase in cellular AcCoA levels, and a ∼85% decrease in anchorage-independent growth compared to the scrambled shRNA cell line. However, the NAT1 shRNA knockdown did not yield significant changes (P > 0.05) in cell doubling time, anchorage-dependent growth or relative invasion ability. Previous studies, using the same NAT1 shRNA knockdown plasmid in a colon adenocarcinoma cell line achieved an 80-90% knockdown of NAT1 10 with significant changes in cell growth and invasion but only a 15% reduction in anchorage-independent cell growth. The differences observed between the present study and the previous NAT1 knockdown study 10 could be due to the different cell line used, our use of the FRT system to minimize the possibilities of off-target effects, the media and culture conditions utilized, or the level of NAT1 knockdown. It is possible there is a threshold knockdown of NAT1 required to observe effects on cell growth and cell invasion that is tissue or cell-type specific.
Despite a 12-fold overexpression of NAT1 in vitro activity, significant (P > 0.05) changes in endogenous AcCoA levels, cell doubling time, anchorage-dependent growth, anchorage-independent cell growth, or relative invasion ability were not observed. In contrast, a previous study using HB4a cells reported that NAT1 overexpression resulted in enhanced growth properties. 3 The MDA-MB-231 cells used in the present study are a claudin-low, triple-negative breast cancer cell line whereas the HB4a cell line is derived from normal luminal mammary epithelial cells. Thus, the lack of differences between scrambled shRNA and NAT1 overexpression MDA-MB-231 cell lines may be a result of the cell line utilized.
Recent reports that NAT1 catalyzes the hydrolysis of AcCoA in the presence of folate suggest that NAT1 may affect endogenous levels of AcCoA. 1 Consistent with this concept, we found that partial NAT1
knockdown by 39% elevated endogenous AcCoA levels by 35%
( Figure 1C ). Although this finding is consistent with AcCoA hydrolysis catalyzed by NAT1, it does not provide evidence this is the primary or sole mechanism for the elevation of AcCoA. Rat embryonic fibroblasts from rapid acetylator congenic rats (high levels of rat NAT2 which is AcCoA levels could provide an explanation for differences observed in metabolites of fatty acid synthesis and amino acids. 33 The effects of NAT1 knockdown on anchorage-independent cell growth and | 555 endogenous AcCoA levels may provide insight into why congenic rapid NAT2 (ortholog to human NAT1) rats develop more mammary tumors than congenic slow NAT2 rats following administration of mammary carcinogens that are not metabolized by rat NAT2. 30 A second objective of this study was to investigate inhibition of NAT1 via a small molecule inhibitor to NAT1 knockdown using shRNA.
We selected a novel small molecule inhibitor (5-HDST) similar to one identified and characterized previously. 22 The scrambled shRNA cell line was utilized as the control in both the small molecular inhibitor and shRNA knockdown experiments to facilitate this comparison. 
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